Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report)’s share price fell 4.6% during trading on Thursday . The company traded as low as $2.31 and last traded at $2.37. 26,650 shares changed hands during mid-day trading, an increase of 1,131% from the average session volume of 2,165 shares. The stock had previously closed at $2.48.
Graybug Vision Stock Performance
The firm has a market capitalization of $3.72 million, a PE ratio of -1.37 and a beta of 1.20. The firm has a fifty day moving average of $2.31 and a 200 day moving average of $2.12.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Read More
- Five stocks we like better than Graybug Vision
- With Risk Tolerance, One Size Does Not Fit All
- How Did Peter Thiel-Backed Crypto Exchange Bullish’s IPO Go?
- Insider Buying Explained: What Investors Need to Know
- Mercury Systems Up 27%: Financials Send Investors a Clear Signal
- What is a penny stock? A comprehensive guide
- Deere’s Sell-Off Could Be a Long-Term Buying Chance
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
